Pulmonary vascular disease & thromboembolismCohort study
Worldwide Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy
- Prospective registry study
- international
- 34 centres in 20 countries
- consecutive patients
Authors' conclusion
This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival.
Study context
- Population
- Newly diagnosed CTEPH, 34 centres in 20 countries, enrolled Feb 2015–Sep 2016, followed until Sep 2019
- Participants
- 1,009 consecutive patients
- Exposure
- Pulmonary endarterectomy (PEA) vs balloon pulmonary angioplasty (BPA) vs no PEA/BPA
- PEAn = 605
- BPAn = 185
- No PEA/BPAn = 219
Main finding
As reported in the abstract
Death during observation period · >3 years; ≤5.6 years
Death during observation period · >3 years; ≤5.6 years
3-year survival (Kaplan-Meier)
- PEA vs BPA: P < 0.001 — death across the 3 groups
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Survival by anticoagulant (VKA vs NOAC) · no survival difference | P = 0.756 |
Original publication
Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy. Circulation. Published 17 September 2024. doi:10.1161/circulationaha.124.068610
Summarised from the published abstract; every number is checked against it